Product Description
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy. MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same patient cohort in which it will be tested. (Sourced from: https://microbiotica.com/microbioticas-live-bacterial-therapeutic-mb097-in-development-to-begin-clinical-trials-in-2022-in-immuno-oncology/)
Mechanisms of Action: Microbiome Modulator
Novel Mechanism: Yes
Modality: Microbiome
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Microbiotica
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Italy, Spain, United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06540391 |
MELODY-1 | P1 |
Active, not recruiting |
Melanoma |
2025-12-01 |
12% |
2025-09-27 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |